Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy

Yuh Min Chen, Reury Perng Perng, Jen Fu Shih, Chun Ming Tsai, Jacqueline Whang-Peng

研究成果: 雜誌貢獻文章

11 引文 (Scopus)

摘要

Our aim was to determine the appropriate salvage regimen for Chinese non-small cell lung cancer (NSCLC) patients who failed previous chemotherapy. We retrospectively analyzed data from our seven clinical trials, including single-agent gemcitabine, gefitinib, docetaxel with a different schedule, vinorelbine plus cisplatin, vinorelbine plus gemcitabine, docetaxel plus gemcitabine, and docetaxel plus ifosfamide, with a total of 342 cases (including 314 patients, of which 28 entered two different trials due to different salvage line settings), and compared these data with those of other studies, addressing the efficacy and toxicity of salvage therapy in patients who failed previous chemotherapy to analyze choosing of an appropriate salvage regimen. Of the 342 cases receiving salvage treatment, 71.1% were in second-line treatment, and 28.9% in third-line or later treatment. The response rate to our salvage therapy ranged widely, from 6.1% to 36.1%. Median survival was between 5.7 and 8.4 months when different salvage chemotherapy regimens were used, whereas it was 9.3 months in those who received gefitinib treatment. Similarly, 1-year survival ranged between 19.7% and 40% in a chemotherapy setting, and 40.8% for gefitinib treatment. Those who received gefitinib had better toxicity profiles than those who received other regimens. Febrile neutropenia occurred in 19 patients who received a chemotherapy agent (6.2%), and four patients died despite granulocyte colony-stimulating factor and antibiotic treatment. Grade 3 or 4 interstitial pneumonitis occurred in 14 of 247 patients (5.7%) who received docetaxel with/without another agent, and 10 patients died. Grade 3 interstitial pneumonitis occurred in one patient who received gefitinib treatment and recovered. In conclusion, both chemotherapeutic agents, such as docetaxel alone or gemcitabine plus vinorelbine, and gefitinib, are probably appropriate salvage regimens for Chinese NSCLC patients who have failed previous chemotherapy. However, gefitinib has a better safety profile and probably better survival than the chemotherapeutic agents and would be an appropriate alternative choice for salvage chemotherapy, even in a second-line setting for Chinese patients.
原文英語
頁(從 - 到)545-550
頁數6
期刊Journal of Thoracic Oncology
1
發行號6
DOIs
出版狀態已發佈 - 七月 1 2006
對外發佈Yes

指紋

Salvage Therapy
docetaxel
Non-Small Cell Lung Carcinoma
gemcitabine
Drug Therapy
Interstitial Lung Diseases
Survival
Therapeutics
Febrile Neutropenia
Ifosfamide
Proxy
Granulocyte Colony-Stimulating Factor
gefitinib
Cisplatin
Appointments and Schedules
Clinical Trials
Anti-Bacterial Agents
Safety

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

引用此文

Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. / Chen, Yuh Min; Perng, Reury Perng; Shih, Jen Fu; Tsai, Chun Ming; Whang-Peng, Jacqueline.

於: Journal of Thoracic Oncology, 卷 1, 編號 6, 01.07.2006, p. 545-550.

研究成果: 雜誌貢獻文章

Chen, Yuh Min ; Perng, Reury Perng ; Shih, Jen Fu ; Tsai, Chun Ming ; Whang-Peng, Jacqueline. / Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. 於: Journal of Thoracic Oncology. 2006 ; 卷 1, 編號 6. 頁 545-550.
@article{7878295e91654148b5d1af635163ec93,
title = "Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy",
abstract = "Our aim was to determine the appropriate salvage regimen for Chinese non-small cell lung cancer (NSCLC) patients who failed previous chemotherapy. We retrospectively analyzed data from our seven clinical trials, including single-agent gemcitabine, gefitinib, docetaxel with a different schedule, vinorelbine plus cisplatin, vinorelbine plus gemcitabine, docetaxel plus gemcitabine, and docetaxel plus ifosfamide, with a total of 342 cases (including 314 patients, of which 28 entered two different trials due to different salvage line settings), and compared these data with those of other studies, addressing the efficacy and toxicity of salvage therapy in patients who failed previous chemotherapy to analyze choosing of an appropriate salvage regimen. Of the 342 cases receiving salvage treatment, 71.1{\%} were in second-line treatment, and 28.9{\%} in third-line or later treatment. The response rate to our salvage therapy ranged widely, from 6.1{\%} to 36.1{\%}. Median survival was between 5.7 and 8.4 months when different salvage chemotherapy regimens were used, whereas it was 9.3 months in those who received gefitinib treatment. Similarly, 1-year survival ranged between 19.7{\%} and 40{\%} in a chemotherapy setting, and 40.8{\%} for gefitinib treatment. Those who received gefitinib had better toxicity profiles than those who received other regimens. Febrile neutropenia occurred in 19 patients who received a chemotherapy agent (6.2{\%}), and four patients died despite granulocyte colony-stimulating factor and antibiotic treatment. Grade 3 or 4 interstitial pneumonitis occurred in 14 of 247 patients (5.7{\%}) who received docetaxel with/without another agent, and 10 patients died. Grade 3 interstitial pneumonitis occurred in one patient who received gefitinib treatment and recovered. In conclusion, both chemotherapeutic agents, such as docetaxel alone or gemcitabine plus vinorelbine, and gefitinib, are probably appropriate salvage regimens for Chinese NSCLC patients who have failed previous chemotherapy. However, gefitinib has a better safety profile and probably better survival than the chemotherapeutic agents and would be an appropriate alternative choice for salvage chemotherapy, even in a second-line setting for Chinese patients.",
keywords = "Gefitinib, Gemcitabine, Non-small cell lung cancer, Salvage therapy, Taxanes",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Shih, {Jen Fu} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/01243894-200607000-00008",
language = "English",
volume = "1",
pages = "545--550",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Shih, Jen Fu

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Our aim was to determine the appropriate salvage regimen for Chinese non-small cell lung cancer (NSCLC) patients who failed previous chemotherapy. We retrospectively analyzed data from our seven clinical trials, including single-agent gemcitabine, gefitinib, docetaxel with a different schedule, vinorelbine plus cisplatin, vinorelbine plus gemcitabine, docetaxel plus gemcitabine, and docetaxel plus ifosfamide, with a total of 342 cases (including 314 patients, of which 28 entered two different trials due to different salvage line settings), and compared these data with those of other studies, addressing the efficacy and toxicity of salvage therapy in patients who failed previous chemotherapy to analyze choosing of an appropriate salvage regimen. Of the 342 cases receiving salvage treatment, 71.1% were in second-line treatment, and 28.9% in third-line or later treatment. The response rate to our salvage therapy ranged widely, from 6.1% to 36.1%. Median survival was between 5.7 and 8.4 months when different salvage chemotherapy regimens were used, whereas it was 9.3 months in those who received gefitinib treatment. Similarly, 1-year survival ranged between 19.7% and 40% in a chemotherapy setting, and 40.8% for gefitinib treatment. Those who received gefitinib had better toxicity profiles than those who received other regimens. Febrile neutropenia occurred in 19 patients who received a chemotherapy agent (6.2%), and four patients died despite granulocyte colony-stimulating factor and antibiotic treatment. Grade 3 or 4 interstitial pneumonitis occurred in 14 of 247 patients (5.7%) who received docetaxel with/without another agent, and 10 patients died. Grade 3 interstitial pneumonitis occurred in one patient who received gefitinib treatment and recovered. In conclusion, both chemotherapeutic agents, such as docetaxel alone or gemcitabine plus vinorelbine, and gefitinib, are probably appropriate salvage regimens for Chinese NSCLC patients who have failed previous chemotherapy. However, gefitinib has a better safety profile and probably better survival than the chemotherapeutic agents and would be an appropriate alternative choice for salvage chemotherapy, even in a second-line setting for Chinese patients.

AB - Our aim was to determine the appropriate salvage regimen for Chinese non-small cell lung cancer (NSCLC) patients who failed previous chemotherapy. We retrospectively analyzed data from our seven clinical trials, including single-agent gemcitabine, gefitinib, docetaxel with a different schedule, vinorelbine plus cisplatin, vinorelbine plus gemcitabine, docetaxel plus gemcitabine, and docetaxel plus ifosfamide, with a total of 342 cases (including 314 patients, of which 28 entered two different trials due to different salvage line settings), and compared these data with those of other studies, addressing the efficacy and toxicity of salvage therapy in patients who failed previous chemotherapy to analyze choosing of an appropriate salvage regimen. Of the 342 cases receiving salvage treatment, 71.1% were in second-line treatment, and 28.9% in third-line or later treatment. The response rate to our salvage therapy ranged widely, from 6.1% to 36.1%. Median survival was between 5.7 and 8.4 months when different salvage chemotherapy regimens were used, whereas it was 9.3 months in those who received gefitinib treatment. Similarly, 1-year survival ranged between 19.7% and 40% in a chemotherapy setting, and 40.8% for gefitinib treatment. Those who received gefitinib had better toxicity profiles than those who received other regimens. Febrile neutropenia occurred in 19 patients who received a chemotherapy agent (6.2%), and four patients died despite granulocyte colony-stimulating factor and antibiotic treatment. Grade 3 or 4 interstitial pneumonitis occurred in 14 of 247 patients (5.7%) who received docetaxel with/without another agent, and 10 patients died. Grade 3 interstitial pneumonitis occurred in one patient who received gefitinib treatment and recovered. In conclusion, both chemotherapeutic agents, such as docetaxel alone or gemcitabine plus vinorelbine, and gefitinib, are probably appropriate salvage regimens for Chinese NSCLC patients who have failed previous chemotherapy. However, gefitinib has a better safety profile and probably better survival than the chemotherapeutic agents and would be an appropriate alternative choice for salvage chemotherapy, even in a second-line setting for Chinese patients.

KW - Gefitinib

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Salvage therapy

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=34247855995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247855995&partnerID=8YFLogxK

U2 - 10.1097/01243894-200607000-00008

DO - 10.1097/01243894-200607000-00008

M3 - Article

C2 - 17409915

AN - SCOPUS:34247855995

VL - 1

SP - 545

EP - 550

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -